Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.

Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr M.

Ann Oncol. 2014 Aug;25(8):1591-7. doi: 10.1093/annonc/mdu129. Epub 2014 Mar 25.

PMID:
24669017
2.

A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma.

Quinton A, Lewis P, Ali P, Morgan C, Bertelli G.

Med Oncol. 2013;30(3):661. doi: 10.1007/s12032-013-0661-1. Epub 2013 Jul 18.

PMID:
23864250
3.

Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.

Shepherd ST, Gillen G, Morrison P, Forte C, Macpherson IR, White JD, Mark PB.

Eur J Cancer. 2014 Mar;50(5):944-52. doi: 10.1016/j.ejca.2013.12.021. Epub 2014 Jan 17.

PMID:
24445148
4.

Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients.

Ainsworth NL, Marshall A, Hatcher H, Whitehead L, Whitfield GA, Earl HM.

Ann Oncol. 2012 Jul;23(7):1845-53. doi: 10.1093/annonc/mdr539. Epub 2011 Nov 21.

PMID:
22104575
5.

Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.

de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC.

Gynecol Oncol. 2006 Dec;103(3):1063-9. Epub 2006 Jul 27.

PMID:
16875719
6.

Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey.

Diminutto A, Basso U, Maruzzo M, Morelli F, De Giorgi U, Perin A, Fraccon AP, Lo Re G, Rizzi A, Sava T, Fornarini G, Valcamonico F, Zustovich F, Massari F, Zanardi E, Roma A, Zattoni F, Zagonel V.

Clin Genitourin Cancer. 2016 Apr;14(2):e161-9. doi: 10.1016/j.clgc.2015.12.009. Epub 2015 Dec 17.

PMID:
26775721
7.

Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.

Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, Lindley C.

Cancer Chemother Pharmacol. 2001 May;47(5):373-9.

PMID:
11391850
8.

Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.

Nagao S, Fujiwara K, Imafuku N, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I.

Gynecol Oncol. 2005 Nov;99(2):327-33. Epub 2005 Jul 11.

PMID:
16005943
9.

Flat dosing of carboplatin is justified in adult patients with normal renal function.

Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.

Clin Cancer Res. 2006 Nov 1;12(21):6502-8.

10.

Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.

Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R.

Aust N Z J Med. 1996 Jun;26(3):372-9.

PMID:
8811211
11.

Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients.

Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG.

Ann Oncol. 2004 Feb;15(2):291-5.

PMID:
14760124
12.

Inaccuracies in estimated glomerular filtration rate in one Australian renal centre.

Brown MA, Pirabhahar S, Kelly JJ, Mangos GJ, Mackenzie C, McConachie P, Janssen J, Smart RC.

Nephrology (Carlton). 2011 Jul;16(5):486-94. doi: 10.1111/j.1440-1797.2011.01453.x.

PMID:
21352419
13.

Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.

Dooley MJ, Poole SG, Rischin D, Webster LK.

Eur J Cancer. 2002 Jan;38(1):44-51.

PMID:
11750838
14.

Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience.

Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T.

Ann Oncol. 2015 Sep;26(9):1865-70. doi: 10.1093/annonc/mdv254. Epub 2015 Jun 2.

PMID:
26037797
15.

Evaluation of renal function in elderly patients: performance of creatinine-based formulae versus the isotopic method using 99mTc-diethylene triamine pentaacetic acid.

Maioli C, Cozzolino M, Gallieni M, Del Sole A, Tagliabue L, Strinchini A, Gaito S, Lecchi M, Cusi D, Lucignani G.

Nucl Med Commun. 2014 Apr;35(4):416-22. doi: 10.1097/MNM.0000000000000066.

PMID:
24457319
16.
17.

Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials.

Hermsen ED, Maiefski M, Florescu MC, Qiu F, Rupp ME.

Pharmacotherapy. 2009 Jun;29(6):649-55. doi: 10.1592/phco.29.6.649.

PMID:
19476418
18.

Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose.

Dooley MJ, Poole SG, Rischin D.

Ann Oncol. 2013 Nov;24(11):2746-52. doi: 10.1093/annonc/mdt300. Epub 2013 Aug 7.

PMID:
23928359
19.

Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size.

Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT.

Clin J Am Soc Nephrol. 2010 Jun;5(6):1003-9. doi: 10.2215/CJN.06870909. Epub 2010 Mar 18.

20.

Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.

Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.

Cancer Chemother Pharmacol. 1998;42(4):307-12.

PMID:
9744776

Supplemental Content

Support Center